| Aug 2 |
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
|
| Jul 10 |
Amylyx jumps on acquisition of Eiger’s GLP-1 drug
|
| Jul 10 |
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
|
| Jul 10 |
Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition
|
| Jul 10 |
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
|
| Jul 10 |
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
|
| Jul 9 |
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
|
| Jun 28 |
Amylyx ventures into metabolic diseases market with $35.1m deal
|
| Jun 25 |
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
|
| Jun 22 |
Amylyx inks deal to buy Eiger’s GLP-1 targeting drug
|
